Benzodiazepines Refusal During Dispensing Process Among Patients Diagnosed With Depression or Schizophrenia in Malaysia
Main Article Content
Abstract
Introduction: Benzodiazepines (BZDs) are commonly prescribed to psychiatric patients. However, there have been few studies evaluating BZD refusal among patients with psychiatric disorders during the dispensing process. Thus, this study aimed to determine 1) the factors associated with BZD refusal during the dispensing process and to determine 2) the association between BZD refusal and psychiatric medication adherence among patients diagnosed with depression or schizophrenia. Method: This study was conducted at the Specialist Clinic Pharmacy, Jerantut Hospital, Malaysia, from May 2018 to June 2018. BZD refusal status was determined after the dispensing process, and general information on BZD was determined using a questionnaire developed by the researchers. Medication adherence was assessed using the Malaysian Medication Adherence Scale (MALMAS). Results: Overall, 75 patients with psychiatric disorders participate in the study. Participants had been on BZD treatment for a mean of 32.8± 21.6 months. The BZD refusal rate was 38.7%. BZD refusal was significantly associated with several factors. A one-year increase in age resulted in increased odds of BZD refusal by 1.16 times (95% CI 1.05-1.27). Other factors were male gender (OR,9.14; 95% CI, 1.17-71.27), being single (OR,15.07; 95% CI, 1.12-184.28), the diagnosis of schizophrenia (OR,13.45; 95% CI, 1.75-10.33) and not having history of illicit drug use (OR,20.63; 95% CI, 2.49-171.0). Medication adherence was not associated with BZD refusal. Conclusion: BZD refusal was significantly associated with demographic factors such as increased age, male gender and being single and diagnosis factors namely schizophrenia diagnosis and not having history of illicit substance use. Thus, the need for BZD in these groups of patients should be reviewed regularly.
Downloads
Article Details
References
Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH. Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neurosci Ther. 2018;24:615-623.
Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M. The early course of schizophrenia and depression*. Eur Arch Psychiatry Clin Neurosci. 2005; 255:167–173.
Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews. 2012;11:CD006391.
Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, Kashima H. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC psychiatry. 2009;9:38
Pfeiffer PN, Ganoczy D, Zivin K, Valenstein M. Benzodiazepines and adequacy of initial antidepressant treatment for depression. Journal of clinical psychopharmacology. 2011;31:360-364.
Fulone I, Silva MT, Lopes LC. Long-term benzodiazepine use in patients taking antidepressants in a public health setting in Brazil: a cross-sectional study BMJ Open 2018;8:e018956.
Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;6:CD001026.
Gurmu AE, Abdela E, Allele B, Cheru E, Amogne B. Rate of nonadherence to antipsychotic medications and factors leading to nonadherence among psychiatric patients in Gondar University Hospital, Northwest Ethiopia. Adv Psychiatry (2014). 2014:475812
Mert DG, Turgut NH, Kelleci M, Semiz M. Perspectives on reasons of medication nonadherence in psychiatric patients. Patient preference and adherence. 2015;9:87.
Al-Jumah KA, Qureshi NA. Impact of pharmacist interventions on patients’ adherence to antidepressants and patient-reported outcomes: a systematic review. Patient preference and adherence. 2012;6:87.
Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care. 2002;40:630–639
Habraken H, De Maeseneer J, De Prins L, Gosset C. Regional differences in the consumption of benzodiazepines: an Analysis from Belgium. Arch Public Health. 2004; 63: 227-241.
Abrogoua DP, Vaubou F, Brou NA, Doffou E. Assessment of benzodiazepines dependence in patients during dispensing at neighbourhood pharmacies in Cote d ’Ivoire. J Hosp Clin Pharm. 2017; 2:14-23
Schallemberger JB, Colet CD. Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil. Trends in psychiatry and psychother. 2016;38:63-70.
Javier I, Barral C, Casado-Espada NM, de Alarcón R, Maciá-Casas A, Hernandez BV, Roncero C. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry research. 2020;284:112660
Leggett A, Kavanagh J, Zivin K, Chiang C, Kim HM, Kales HC. The association between benzodiazepine use and depression outcomes in older veterans. Journal of Geriatric Psychiatry and Neurology. 2015; 28: 281–287.
Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry.2004;161:654-661.
Kaufmann CN, Spira AP, Depp CA, Mojtabia R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics from 1999-2014: Results from the National Health and Nutrition Examination Survey. Psychiatr Serv. 2018;69:235–238
Bekker CL, Van Den Bemt BJ, Egberts AC, Bouvy ML, Gardarsdottir H. Patient and medication factors associated with preventable medication waste and possibilities for redispensing. Int jour of clin pharm. 2018;40:704-711.
Hashimoto Y, Tensho M. Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study. BMC Health Services Research. 2016 ;16:150.
Ogbonna CI, Lembke A. Tapering Patients Off of Benzodiazepines. Am Fam Physician. 2017;96:606-610.
Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Oxf). 2005;27:281-291
Chung WW, Chua SS, Lai PS, Morisky DE. The Malaysian Medication Adherence Scale (MALMAS): Concurrent Validity Using a Clinical Measure among People with Type 2 Diabetes in Malaysia. PLoS One. 2015;10:e0124275
Torres-Bondia, F, de Batlle, J, Galván L, Buti M, Barbe F, Pinol-Ripoll G. Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015. BMC Public Health 2020;20;818.
Zhong XM, Wang F, Zhang Q, Ungvari GS, Ng CH, Chiu HFK et al. Concurrent benzodiazepine use in older adults treated with antidepressants in Asia. Int Psychogeriatr. 2019;31:685-689
el-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? The Canadian Journal of Psychiatry. 2010;55:709-714.
Marks JR, Schectman JM, Groninger H, Plews-Ogan ML. The association of health literacy and socio-demographic factors with medication knowledge. Patient Educ Couns. 2010;78:372-376
Jacob SA, Ab Rahman AF, Hassali MA. Attitudes and beliefs of patients with chronic depression toward antidepressants and depression. Neuropsychiatr Dis Treat. 2015;11:1339-1347.
Fawzi W, Abdel Mohsen MY, Hashem AH, Moussa S, Coker E, Wilson KC. Beliefs about medications predict adherence to antidepressants in older adults. Int Psychogeriatr. 2012;24:159-69.
Rizvi SJ, Cyriac A, Grima E, Tan M, Lin P, Gallaugher LA et al. Depression and employment status in primary and tertiary care settings. The Canadian Journal of Psychiatry. 2015;60:14-22.
Airagnes G, Lemogne C, Renuy A, Goldberg M, Hoertel N, Roquelaure Y et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: Findings from the CONSTANCES cohort. BMC Public Health. 2019;19:566
Canham SL, Gallo J, Simoni-Wastila L. Perceptions of benzodiazepine dependence among women age 65 and older. J Gerontol Soc Work. 2014;57:872-888.
Patel MJ, Ahmer S, Khan F, Qureshi A.W, Shehzad MF, Muzaffar S. Benzodiazepine use in medical out-patient clinics: A study from a developing country. Journal of Pakistan Medical Association. 2013; 63: 717-720.
Sjöstedt C, Ohlsson H, Li X, Sundquist K. Socio-demographic factors and long-term use of benzodiazepines in patients with depression, anxiety or insomnia. Psychiatry Res. 2017; 249:221–225
West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall Accuracy for Prescription Medications: Self-report Compared with Database Information, American Journal of Epidemiology. 1995;142:1103–1112
Menif L, Oueslati B, Maamri A, Melki W, Zalila H. Correlates of benzodiazepine dependence in patients with depression followed up in a psychiatric outpatient unit in Tunisia. J Ethn Subst Abuse. 2019;ePub(ePub):1-13
Deng X, Huang Z, Li X, Li Y, Wang Y, Wu D et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use. Shanghai Arch Psychiatry. 2012;24:271-278.
Liebrenz M, Schneider M, Buadze A, Gehring MT, Dube A, Caflisch C. Attitudes towards a maintenance (-agonist) treatment approach in high-dose benzodiazepine-dependent patients: a qualitative study. Harm Reduct J. 2016;13:1.